550 related articles for article (PubMed ID: 30628)
21. [Regulation of cerebral circulation by neurotransmitters].
Jia WG
Sheng Li Ke Xue Jin Zhan; 1984 Jul; 15(3):214-7. PubMed ID: 6151253
[No Abstract] [Full Text] [Related]
22. Treatment of tardive dyskinesia: other therapies.
Tanner CM
Clin Neuropharmacol; 1983 Jun; 6(2):159-67. PubMed ID: 6133620
[No Abstract] [Full Text] [Related]
23. Functional mechanism of the striatum by integration of nine types of synapses which have at least seven different transmitters.
Hassler R
Int J Neurol; 1979; 13(1-4):94-116. PubMed ID: 45452
[No Abstract] [Full Text] [Related]
24. Recent advances in neuropharmacology of neurological interest.
Curtis DR
Proc Aust Assoc Neurol; 1968; 5(1):101-7. PubMed ID: 4388201
[No Abstract] [Full Text] [Related]
25. Brain neurotransmitters regulating TRH producing neurons.
Annunziato L; Di Renzo G; Quattrone A; Schettini G; Preziosi P
Pharmacol Res Commun; 1981 Jan; 13(1):1-10. PubMed ID: 6111810
[No Abstract] [Full Text] [Related]
26. Effects of precursors on brain neurotransmitter synthesis and brain functions.
Fernstrom JD
Diabetologia; 1981 Mar; 20 Suppl():281-9. PubMed ID: 6112187
[TBL] [Abstract][Full Text] [Related]
27. [Mechanism of action of antiepileptic drugs. Experimental results on the role of neurotransmitters (author's transl)].
Löscher W
Nervenarzt; 1981 Feb; 52(2):61-7. PubMed ID: 6111757
[No Abstract] [Full Text] [Related]
28. Serotonergic-dopaminergic interactions and extrapyramidal function.
Chase TN
Adv Biochem Psychopharmacol; 1974; 11(0):377-85. PubMed ID: 4367649
[No Abstract] [Full Text] [Related]
29. [Biochemical aspects of Huntington's disease].
Bonilla E
Acta Cient Venez; 1977; 28(6):391-7. PubMed ID: 24971
[No Abstract] [Full Text] [Related]
30. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
Jeste DV; Wyatt RJ
J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
[TBL] [Abstract][Full Text] [Related]
31. 5-HT receptor regulation of neurotransmitter release.
Fink KB; Göthert M
Pharmacol Rev; 2007 Dec; 59(4):360-417. PubMed ID: 18160701
[TBL] [Abstract][Full Text] [Related]
32. [Problems and future perspectives in the treatment of Parkinson's disease].
Hens L; Hellemans J
Tijdschr Gerontol Geriatr; 1982 Aug; 13(4):147-54. PubMed ID: 6127822
[TBL] [Abstract][Full Text] [Related]
33. Neurochemical transmission, neurotransmitters, and clinical correlations.
Stewart CM
J Neurosurg Nurs; 1982 Dec; 14(6):303-8. PubMed ID: 6129291
[No Abstract] [Full Text] [Related]
34. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
[No Abstract] [Full Text] [Related]
35. The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias).
Marsden CD
Mod Trends Neurol; 1975; 6():141-66. PubMed ID: 127927
[No Abstract] [Full Text] [Related]
36. CNS at the cellular level: identity of transmitter agents.
Hebb C
Annu Rev Physiol; 1970; 32():165-92. PubMed ID: 4391932
[No Abstract] [Full Text] [Related]
37. [Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry].
Bartholini G
Schweiz Arch Neurol Neurochir Psychiatr; 1979; 125(2):265-9. PubMed ID: 45343
[TBL] [Abstract][Full Text] [Related]
38. New approaches to the study of the neurochemical basis of sleep and wakefulness.
Drucker-Colín RR; Rojas-Ramírez JA
Adv Psychobiol; 1976; 3():1-34. PubMed ID: 9792
[No Abstract] [Full Text] [Related]
39. Central neurotransmitters in aggression.
Reis DJ
Res Publ Assoc Res Nerv Ment Dis; 1974; 52():119-48. PubMed ID: 4473807
[No Abstract] [Full Text] [Related]
40. Brain neurotransmitters and the development and maintenance of experimental hypertension.
Buccafusco JJ; Brezenoff HE
Prog Drug Res; 1986; 30():127-50. PubMed ID: 2880367
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
